Research programme: skin aging - Anaderm
Latest Information Update: 05 Sep 2006
At a glance
- Originator Anaderm Research
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Skin aging
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Skin aging in USA (Topical)
- 03 Oct 2001 Preclinical development for Skin aging in USA (Topical)